SCHEMBL282881

SCHEMBL282881

CCC(CC)c1ccccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.68
GABRA1 P14867 2/20 0.56
GABRB2 P47870 2/20 0.56
POLB P06746 2/20 0.44
LMNA P02545 4/20 0.41
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CA2 P00918 2/20 0.41
CYP3A4 P08684 2/20 0.41
BLM P54132 2/20 0.41
HIF1A Q16665 2/20 0.41
NPC1 O15118 1/20 0.41
CA12 O43570 1/20 0.41
GMNN O75496 1/20 0.41
EGFR P00533 1/20 0.41
FYN P06241 1/20 0.41
CA3 P07451 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28298200 0.87 TSHR (0.59) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL2300700 0.87 TSHR (0.59) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL982520 0.87 TSHR (0.59) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL20319876 0.86 TSHR (0.62) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL27946949 0.84 TSHR (0.55) TSHRGABRA1GABRB2POLBESR1
SCHEMBL980886 0.84 TSHR (0.55) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL6535416 0.84 TSHR (0.65) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL982869 0.83 TSHR (0.53) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL13857861 0.82 TSHR (0.53) TSHRGABRA1GABRB2POLBLMNA
SCHEMBL981301 0.82 TSHR (0.53) TSHRGABRA1GABRB2POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132049-A1 METHOD FOR PRODUCING IRON OXIDE MAGNETIC PARTICLES, AND IRON OXIDE MAGNETIC PARTICLES FORMED THEREFROM ZTI BIOSCIENCES CO LTD (KR) 2026-05-14 US disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
US-20240132445-A1 PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS Hinye Pharmaceutical Co., Ltd. (CN) 2024-04-25 US disclosed
WO-2024080664-A1 METHOD FOR PRODUCING IRON OXIDE BASED NANOPARTICLES, AND IRON OXIDE BASED NANOPARTICLES FORMED THEREFROM 주식회사 지티아이바이오사이언스 2024-04-18 WO disclosed
US-20240027908-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2024-01-25 US disclosed
EP-4286359-A1 PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS Hinye Pharmaceutical Co., Ltd. (CN) 2023-12-06 EP disclosed
US-20230251572-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-08-10 US disclosed
CN-115175887-B Phenol derivatives and their use in medicine 天地恒一制药股份有限公司 2023-08-01 CN disclosed
CN-113929866-B Modified resin and resin composition 旭化成株式会社 2023-07-07 CN disclosed
EP-1611227-A1 DI-SECONDARY ALKYL HINDERED PHENOL ANTIOXIDANTS THE LUBRIZOL CORPORATION (US) 2006-01-04 EP disclosed
WO-2005051298-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2005-06-09 WO disclosed
WO-2004094577-A1 DI-SECONDARY ALKYL HINDERED PHENOL ANTIOXIDANTS THE LUBRIZOL CORPORATION (US) 2004-11-04 WO disclosed
US-20040198615-A1 Di-secondary alkyl hindered phenol antioxidants THE LUBRIZOL CORPORATION 2004-10-07 US disclosed
EP-0435681-A1 Chroman esters of phenols and benzoic acids having retinoid-like activity ALLERGAN, INC. (US) 1991-07-03 EP disclosed
US-5006550-A Skin disorder, arthritis, wound healing agents, dry eye syndrome ALLERGAN, INC. (US) 1991-04-09 US disclosed
EP-0083839-B1 PROCESS FOR PRODUCING INORGANIC FIBER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1986-03-05 EP disclosed
US-4495121-A SPINNING A POLYMETALOXANE, CALCINING SUMITOMO CHEMICAL COMPANY, LTD. (JP) 1985-01-22 US disclosed
EP-0083839-A2 Process for producing inorganic fiber SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-07-20 EP disclosed
US-4308180-A TIRE TREADS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132445-A1 PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS GABRA2, GABRA1, GABRA4 TSHR 680/4885GABRA1 2/4885GABRB2 7/4885
US-20260132049-A1 METHOD FOR PRODUCING IRON OXIDE MAGNETIC PARTICLES, AND IRON OXIDE MAGNETIC PARTICLES FORMED THEREFROM FASN, AIFM2, SFXN1 TSHR 1967/4885GABRA1 2927/4885GABRB2 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.